Table 1.
The clinical features, diagnosis, and treatment outcome of cases
| Diagnostic method |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Age (year) | Sex | P/H VL | Past Treatment history | Fever | Spleen size (cm) | Liver size (cm) | Lesion Type | BMA/SA | Skin smear | rK39 | Treatment outcome* |
| 1 | 25 | F | No | _ | Yes | 1 | 1 | M, P | BM+ 4ve | + 3ve | + ve | Cured |
| 2 | 20 | M | Yes | SAG | Yes | 1 | 1 | M,P | BM+ 4ve | + 2ve | + ve | Cured |
| 3 | 14 | M | No | _ | Yes | 6 | 2 | M | BM+ 3ve | + 2ve | + ve | Cured |
| 4 | 50 | M | Yes | Mil. | Yes | 4 | 1 | M | BM+ 2ve | + 4ve | + ve | Cured |
| 5 | 36 | M | Yes | SAG | Yes | 5 | 2 | M | SA+ 4ve | + 1ve | + ve | Cured |
| 6 | 40 | M | Yes | Mil. | Yes | 8 | 4 | M,P,N | SA+ 3ve | + 2ve | + ve | Cured |
| 7 | 15 | M | No | _ | Yes | 5 | 1 | M | SA+ 3ve | + 1ve | + ve | Cured |
| 8 | 18 | F | No | _ | Yes | 14 | 1 | M | SA+ 4ve | + 1ve | + ve | Cured |
| 9 | 25 | F | yes | SAG | Yes | 10 | 2 | M,P | SA+1ve | + 4ve | + ve | Cured |
Notes: BMA: Bone marrow aspiration, SA: Splenic aspiration, P/H: Past history, VL: Visceral Leishmaniasis, PKDL: Post-kala-azar dermal leishmaniasis, SAG: Sodium antimony gluconate, SDA: Single-dose AmBisome, Mil.: Miltefosine PS: Parasitic score, M: Macular, P: Papular, N: Nodular, M: Male, F: Female.
*
Each case was first treated for VL with single-dose AmBisome (10 mg/kg) and followed by Miltefosine (2.5 mg/kg/daily) 50 mg twice a day for 12 weeks for PKDL.